The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

NCT07257653 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms
RAS
BRAF
Cetuximabβ
Fruquintinib

Interventions

DRUG: Cetuximab β；Fruquintinib；
DRUG: Cetuximab β；Fruquintinib；anti-PD1 antibody；
DRUG: Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody

Sponsor

Zhejiang University